-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the proxy statement signed by Regeneron shareholders in 2022 shows that its chief executive officer (CEO) Leonard S.
Schleifer will receive a salary of $6.
47 million in 2021, a salary reduction of 95% compared to 2020.
%
.
Chief Scientific Officer (CSO) George D.
Yancopoulos has revenue of $134 million in 2021, down 95% from last year
.
In this regard, analysts believe that the decline in the salary of Leonard Schleifer and George Yancopoulos is expected, and most of their 2020 salaries are linked to up-front equity awards
.
According to the plan, Regeneron CEO and CSO will not receive further equity awards until December 2025
.
In addition, Regeneron has also decided to change the three-year executive compensation vote to an annual one
.
At present, in addition to the salary cuts of Regeneron’s CEO and chief scientific officer, according to the author, many corporate executives have also received salary cuts
.
Among them, the CEO of BioNTech's income in 2021 is somewhat unsatisfactory, but the salary is reduced by 3.
24% compared with the previous year
.
However, it is understood that this is mainly due to the $7.
4 million in compensation Ugur Sahin received in 2020, most of which was due to stock options
.
AstraZeneca CEO Pascal Soriot's salary in 2021 reached $18.
76 million, but it also fell by 10% in relative terms
.
Additionally, Eli Lilly CEO David Ricks' 2021 compensation of $21.
5 million is a 9% drop from his 2020 salary of $23.
7 million
.
The decline was mainly due to a slump of $3.
4 million in the value of its pension
.
The salaries of executives of pharmaceutical companies are actually closely related to corporate performance.
Therefore, due to the good performance of some pharmaceutical companies, many executives still ushered in salary increases
.
For example, with the help of the new crown business, Pfizer's pharmaceutical business revenue continued to improve after the divestiture of the generic drug division Pfizer Upjohn
.
Its CEO's revenue also jumped 16% to $24.
35 million
.
In addition, it is worth noting that Moderna, which is also a manufacturer of mRNA new crown vaccines, saw its CEO’s salary increase by 41% last year, which is also the highest salary increase in the list, reaching $18.
2 million, and the company also relies on this The vaccine was successfully squeezed into the TOP20 list of global pharmaceutical companies by revenue
.
The CEO of Merck changed last year.
Frazier, the former CEO, stepped down on June 30, 2021, and the current CEO Davis took office the next day, but the two people’s combined annual salary was 28.
9 million US dollars, which was a 31% increase from Frazier’s single annual salary in the previous year
.
Johnson & Johnson has two major sectors, pharmaceuticals and devices, in the medical field
.
Therefore, its CEO Alex Gorsky also topped the table with an annual salary of $26.
74 million in his last year in office
.
It is understood that Alex Gorsky has stepped down on January 3, 2022
.
In general, the compensation of CEOs, presidents, general managers and other executives of pharmaceutical companies is basically closely related to the company's revenue, showing the consistency between the interests of the company's executives and the development of the company
.
Although many executives of pharmaceutical companies have received salary cuts in recent years due to changes in the market, in fact, some well-adjusted companies will still achieve good revenue in 2021, and executives' salaries will not fall but rise
.
In the future, with the gradual control of the epidemic and the accelerated reform of enterprises, it is expected that there will be further changes in the salaries of domestic and foreign pharmaceutical companies in 2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Schleifer will receive a salary of $6.
47 million in 2021, a salary reduction of 95% compared to 2020.
%
.
Chief Scientific Officer (CSO) George D.
Yancopoulos has revenue of $134 million in 2021, down 95% from last year
.
In this regard, analysts believe that the decline in the salary of Leonard Schleifer and George Yancopoulos is expected, and most of their 2020 salaries are linked to up-front equity awards
.
According to the plan, Regeneron CEO and CSO will not receive further equity awards until December 2025
.
In addition, Regeneron has also decided to change the three-year executive compensation vote to an annual one
.
At present, in addition to the salary cuts of Regeneron’s CEO and chief scientific officer, according to the author, many corporate executives have also received salary cuts
.
Among them, the CEO of BioNTech's income in 2021 is somewhat unsatisfactory, but the salary is reduced by 3.
24% compared with the previous year
.
However, it is understood that this is mainly due to the $7.
4 million in compensation Ugur Sahin received in 2020, most of which was due to stock options
.
AstraZeneca CEO Pascal Soriot's salary in 2021 reached $18.
76 million, but it also fell by 10% in relative terms
.
Additionally, Eli Lilly CEO David Ricks' 2021 compensation of $21.
5 million is a 9% drop from his 2020 salary of $23.
7 million
.
The decline was mainly due to a slump of $3.
4 million in the value of its pension
.
The salaries of executives of pharmaceutical companies are actually closely related to corporate performance.
Therefore, due to the good performance of some pharmaceutical companies, many executives still ushered in salary increases
.
For example, with the help of the new crown business, Pfizer's pharmaceutical business revenue continued to improve after the divestiture of the generic drug division Pfizer Upjohn
.
Its CEO's revenue also jumped 16% to $24.
35 million
.
In addition, it is worth noting that Moderna, which is also a manufacturer of mRNA new crown vaccines, saw its CEO’s salary increase by 41% last year, which is also the highest salary increase in the list, reaching $18.
2 million, and the company also relies on this The vaccine was successfully squeezed into the TOP20 list of global pharmaceutical companies by revenue
.
The CEO of Merck changed last year.
Frazier, the former CEO, stepped down on June 30, 2021, and the current CEO Davis took office the next day, but the two people’s combined annual salary was 28.
9 million US dollars, which was a 31% increase from Frazier’s single annual salary in the previous year
.
Johnson & Johnson has two major sectors, pharmaceuticals and devices, in the medical field
.
Therefore, its CEO Alex Gorsky also topped the table with an annual salary of $26.
74 million in his last year in office
.
It is understood that Alex Gorsky has stepped down on January 3, 2022
.
In general, the compensation of CEOs, presidents, general managers and other executives of pharmaceutical companies is basically closely related to the company's revenue, showing the consistency between the interests of the company's executives and the development of the company
.
Although many executives of pharmaceutical companies have received salary cuts in recent years due to changes in the market, in fact, some well-adjusted companies will still achieve good revenue in 2021, and executives' salaries will not fall but rise
.
In the future, with the gradual control of the epidemic and the accelerated reform of enterprises, it is expected that there will be further changes in the salaries of domestic and foreign pharmaceutical companies in 2022
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
